ACS Nano · 2020 · 118 citations · 38 references
PharmacyNeurosciencePharmaceuticsAntibody EngineeringDrug DeliveryTargeted Drug DeliveryAmyloid FormationBlood-brain Barrier DeliveryBrain Targeted DeliveryNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsAmyloid Beta AggregationAntibodiesAntibody-mediated Brain TargetingBlood-brain Barrier PermeabilityFab Antibody FragmentsNanocarrier Surface FunctionalizationTargeted Delivery Across The Blood-brain BarrierTherapeutic Antibody Delivery To The Brain
Delivering therapeutic antibodies into the brain across the blood–brain barrier at a therapeutic level is a promising while challenging approach in the treatment of neurological disorders. Here, we present a polymeric nanomicelle (PM) system capable of delivering therapeutically effective levels of 3D6 antibody fragments (3D6-Fab) into the brain parenchyma for inhibiting Aβ aggregation. PM assembly was achieved by charge-converting 3D6-Fab through pH-sensitive citraconylation to allow complexation with reductive-sensitive cationic polymers. Brain targeting was achieved by functionalizing the PM surface with glucose molecules to allow interaction with recycling glucose transporter (Glut)-1 proteins. Consequently, 41-fold enhanced 3D6-Fab accumulation in the brain was achieved by using the PM system compared to free 3D6-Fab. Furthermore, therapeutic benefits were obtained by successfully inhibiting Aβ1–42 aggregation in Alzheimer’s disease mice systemically treated with 3D6-Fab-loaded glucosylated PM. Hence, this nanocarrier system represents a promising method for effectively delivering functional antibody agents into the brain and treating neurological diseases.
38
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3.1K citations
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos, Jirong Lu, Ying Tang et al. · Neuron · 2012 · 461 citations · Full text